Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults.
The clinical outlook for adults with acute lymphoblastic leukemia (ALL) has improved with the use of intensive chemotherapy. Complete remissions (CR) are achieved in 80% of adults but the majority relapse on maintenance chemotherapy and a few exhibit primary resistance to induction therapy. This report compares the various salvage treatments and provides guidance in selecting a regimen with the optimum clinical outcome. Regimens using high-dose ara-C (HDAC) in combination with mitoxantrone, amsacrine, or idarubicin are superior to HDAC alone or with L-asparaginase. The sequential administration of methotrexate and L-asparaginase is equally effective. The duration of second CR is short for all chemotherapeutic regimens.
Welborn
J L
JL
Department of Internal Medicine, University of California, Davis 95816.
D000328:Adult; D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001217:Aspartate-Ammonia Ligase / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015994:Incidence; D008727:Methotrexate / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012008:Recurrence; D016879:Salvage Therapy
D000677:Amsacrine; D003561:Cytarabine; D008942:Mitoxantrone; D001217:Aspartate-Ammonia Ligase; D008727:Methotrexate; D015255:Idarubicin